Brief: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial And Celz-201 (Olastrocel) In The Treatment Of Chronic Lower Back Pain
13/01/2026 14:17
Jan 13 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O: CREATIVE MEDICAL TECHNOLOGY HOLDINGS REACHES MAJOR CLINICAL INFLECTION POINT WITH POSITIVE INTERIM DATA FROM ADAPT TRIAL AND CELZ-201 (OLASTROCEL) IN THE TREATMENT OF CHRONIC LOWER BACK PAIN Source text: ID:nGNX8ZvFjl Further company coverage: CELZ.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM